DAFTAR PUSTAKA

Abbas, K.A., Lichtman, A.H., and Pober, J.S. 2000. Cytokin in Cellular and Moleculer Immunology 4th ed.Philadelphia, WB Saunders; 233-267.

Aini, N, et al. 2008, *Karakteristik Biologis dan Diferensiasi Stem Cell: Fokus pada Mesenchymal Stem Cell*, cdk,161.

Bao P , et al.(2009). The role of vascular Endhothelial Growth Factor in Wound Healing. *J Surg Res* , 347-358.

Benedict CA, Ware CF. TRAIL: not just for tumors anymore? The Journal of experimental medicine.2012; PubMed Central 209(11):1903–6.

Berk V. D. ,& B. J.-V. (2010). Mesenchymal stem cells respond to TNF but do not produce TNF. *Journal of Leukocyte Biology* , 283-289.

Bo Z., & S. Y. (2012). Co-culture of Mesenchymal Stem Cells with Umbilical Vein Endothelial. *Med Sci* , 173-180.

Chun-yu L. , et al. (2015). Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. *Stem Cell Research & Theraphy* .

Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21(1): 21-6.

Fulda, S.; Gorman, A.M.; Hori, O.; Samali, A. Cellular stress responses: cell survival and cell death. *Int J. Cell Bi**ol., 2010*, 214074.

Hoeben A, Landy B, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2008; 56: 549-80.

Honda I , A. T. (2015). Mesenchymal Stem Cells ameliorate intra-amniotic inflamation relatedneonatal complications in rats. *Inflamation and Regeneration* , 261-268.

Hoogdujin M. J. , & f. p. (2010). The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. *international immunopharmacology* .

Huang C. & A. P. (2013). Cell Memory and Adaptation in Chemotaxis. PNAS. 15287-15288.

Huang L. , et al. (2010). Ulceration and Delayed Healing Following Pressure Loading in Hyperglycemic Rats With an Immature Dermal Collagen Fiber Network. *wounds* , 237-244.

Johnson K., W. T. (2013). Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutanepous Wound Repair. Wound Healing Society. 647-661.

Kang S. K. , I. s. (2012). journey of mesenchymal stem cells for homing:strategies to enhance efficancy and safety of stem cell therapy. *stem cells international* .

Kwon Y. W. ,& S. C. (2013). Tumor necrosis factor-α-activated mesenchymal stem cells promote Tumor necrosis factor-. *Biochimica et Biophysica Acta* , 2136-2144.

Li X, et al.(2015). High Concentrations of TNF-α Induce Cell Death during Interactions between Human Umbilical Cord Mesenchymal Stem Cells and Peripheral Blood Mononuclear Cells. Plos One: 10(5): e0128647

Liu Y, et al. 2011. Mesenchymal stem cell-based tissue regenerationis governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nature medicine. 17(12):1594–601.

Marr R.A., Pet., et al., 2010, *Insights into Neurogenesis and Aging: Potential Therapy for Degenerative Disease?* Future Neurology, USA, 527-541.

Nauta,A. J. & W. E. Fibbe. 2007. Immunomodulatory properties of mesenchymal stromal cells. *Blood*, vol. 110, no. 10, pp. 3499–3506.

Setiawan B., 2006, *Aplikasi Terapeutik Sel Stem Embrionik pada Berbagai Penyakit Degeneratif*, cdk, 153.

Shi J.X. et al. 2011. MK2 posttranscriptionally regulates TNF-α-induced expression of ICAM-1 and IL-8 via tristetraprolin in human pulmonary microvascular endothelial cells. *AJP-Lung Cell Mol Physiol*, L793-L799

Shin H. S. ,& H. Y. (2012). The Effect of Platelet-rich Plasma on Wounds of OLETF Rats Using Expression of Matrix Metalloproteinase-2 and -9 mRNA. *Archieves of Plastic Surgery* , 106-112.

Sukhanov, S.,et al. Delafontaine, P.2007. *IGF-1 Reduces Inflammatory Responses, suppresses Oxidative Stress, and Decreases Atheroschlerosis Progresion in ApoE-Deficient Mice*. Arterioscler Thromb Vasc Biol.27;84-2690.Wu H, & S. G. (2009). Structure and Function of Tumor Necrosis Factor at the cell. In E. A. Ralph A Bradshaw, *Handbook of cell signaling* (pp. 265-275). Oxford: Academic Press.

Wang, M., et al. 2006. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. *Am J Physiol Regul Integr Comp Physiol* 291: R880–R884.

Wang, M., et al. 2007. STAT3 Mediates Bone Marrow Mesenchymal Stem Cell VEGF Production. *J Mol Cell Cardiol*; 42(6): 1009–1015.

Wang, P., et al. 2013. MicroRNA-329 suppresses angiogenesis by targeting CD146. MCB.00343-13.

Yoshida S., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factorin tumor necrosis factor alpha-dependent angiogenesis. Mol Cel Biol; 17(7): 4015-23.

Yudistian, S. A., et al. 2016. Injeksi Serum Mengandung TNF-α Tinggi menurunkan Konsentrasi VEGF dan Ekspresi Nephrin Glomerulus Mencit Bunting. Jurnal Kedokteran Brawijaya:10-13.

Zubkova, E. S. , et al. 2016. Regulation of Adipose Tissue Stem Cells Angiogenic Potential by Tumor Necrosis Factor-Alpha. Journal of Cellular Biochemistry 117:180–196